Last reviewed · How we verify

NCT04239014: DUETTE

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Withdrawn Phase 2 Last updated 10 March 2021
What this trial tests

Phase 2 trial testing Olaparib in Ovarian Cancer. Withdrawn.

Timeline
7 August 2020
Primary endpoint
25 January 2021
25 January 2021

Quick facts

Lead sponsorAstraZeneca
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Start date7 August 2020
Primary completion25 January 2021
Estimated completion25 January 2021
Sites26 locations across Italy, Canada, United States, Spain

Drugs / interventions tested

Conditions studied

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the effectiveness and tolerability of a second maintenance treatment in participants with platinum-sensitivity relapsed (PSR) epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (complete response \[CR\] or partial response \[PR\]) or stable disease (SD) from further platinum based chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.
    Huang R, Zhou PK. · · 2021 · cited 557× · PMID 34238917 · DOI 10.1038/s41392-021-00648-7
  2. Targeting replication stress in cancer therapy.
    da Costa AABA, Chowdhury D, Shapiro GI, D'Andrea AD, et al · · 2023 · cited 274× · PMID 36202931 · DOI 10.1038/s41573-022-00558-5
  3. Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.
    McMullen M, Karakasis K, Madariaga A, Oza AM. · · 2020 · cited 127× · PMID 32560564 · DOI 10.3390/cancers12061607
  4. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
    Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6
  5. Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
    Gupta N, Huang TT, Horibata S, Lee JM. · · 2022 · cited 89× · PMID 35259479 · DOI 10.1016/j.phrs.2022.106162
  6. Targeting the replication stress response through synthetic lethal strategies in cancer medicine.
    Ngoi NYL, Pham MM, Tan DSP, Yap TA. · · 2021 · cited 78× · PMID 34215565 · DOI 10.1016/j.trecan.2021.06.002
  7. TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy.
    Singh DD, Yadav DK. · · 2021 · cited 76× · PMID 34440080 · DOI 10.3390/biomedicines9080876
  8. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
    Luo L, Keyomarsi K. · · 2022 · cited 56× · PMID 35435784 · DOI 10.1080/13543784.2022.2067527

Verify or expand the search:

Other trials of Olaparib

Trials testing the same drug.

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

Other AstraZeneca trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04239014.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing